p.96 抽出テキスト

study. Arterioscler Thromb Vasc Biol 2015;35:2700–6. https://doi.org/10.1161/atvbaha. 115.306284 119. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 2023;401:1293–301. https://doi.org/10.1016/S0140-6736(23)00215-5 120. Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary highrisk patients with statin intolerance. Circulation 2024;149:28–35. https://doi.org/10. 1161/CIRCULATIONAHA.123.066213 121. Bohula EA, Giugliano RP, Leiter LA, Verma S, Park J-G, Sever PS, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation 2018;138:131–40. https://doi. org/10.1161/circulationaha.118.034032 122. Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J 2022;43:3198–208. https://doi.org/10.1093/eurheartj/ehab841 123. Byrne P, Demasi M, Jones M, Smith SM, O’Brien KK, DuBroff R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med 2022;182:474–81. https://doi.org/10.1001/jamainternmed.2022.0134 124. Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol 2021;77:1564–75. https://doi.org/10.1016/j.jacc.2020.11.079 125. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation 2018;138:141–9. https://doi.org/ 10.1161/CIRCULATIONAHA.118.034645 126. Waksman R, Merdler I, Case BC, Waksman O, Porto I. Targeting inflammation in atherosclerosis: overview, strategy and directions. EuroIntervention 2024;20:32–44. https://doi.org/10.4244/EIJ-D-23-00606 127. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021;397: 2060–9. https://doi.org/10.1016/S0140-6736(21)00520-1 128. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316: 1289–97. https://doi.org/10.1001/jama.2016.13985 129. Arant CB, Wessel TR, Olson MB, Bairey Merz CN, Sopko G, Rogers WJ, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women’s Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 2004;43:2009–14. https://doi.org/10.1016/j.jacc.2004.01.038 130. da Silveira AD, Ribeiro RA, Rossini AP, Stella SF, Ritta HAR, Stein R, et al. Association of anemia with clinical outcomes in stable coronary artery disease. Coron Artery Dis 2008; 19:21–6. https://doi.org/10.1097/MCA.0b013e3282f27c0a 131. Muzzarelli S, Pfisterer M; Time Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006;152:991–6. https:// doi.org/10.1016/j.ahj.2006.06.014 132. Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif J-C, Tendera M, et al. Hemoglobin and change in hemoglobin status predict mortality, cardiovascular events, and bleeding in stable coronary artery disease. Am J Med 2017;130:720–30. https://doi.org/10.1016/ j.amjmed.2017.01.002 133. Asif A, Wei J, Lauzon M, Sopko G, Reis SE, Handberg E, et al. Anemia and long-term cardiovascular outcomes in women with suspected ischemia—the Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J Plus Cardiol Res Pract 2021;10:100059. https:// doi.org/10.1016/j.ahjo.2021.100059 134. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007;4:e270. https://doi.org/10.1371/journal.pmed.0040270 135. Bartnik M, Ryden L, Malmberg K, Ohrvik J, Pyorala K, Standl E, et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007;93:72–7. https://doi.org/10.1136/hrt.2005.086975 136. Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, et al. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology. Eur Heart J 2015;36:1171–7. https://doi. org/10.1093/eurheartj/ehv008 137. Corona G, Croce L, Sparano C, Petrone L, Sforza A, Maggi M, et al. Thyroid and heart, a clinically relevant relationship. J Endocrinol Invest 2021;44:2535–44. https://doi.org/10. 1007/s40618-021-01590-9 138. Sohn SY, Lee E, Lee MK, Lee JH. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis and systematic review of cohort studies. Endocrinol Metab (Seoul) 2020;35:786–800. https://doi.org/10.3803/EnM.2020.728 139. Winther S, Schmidt SE, Mayrhofer T, Bøtker HE, Hoffmann U, Douglas PS, et al. Incorporating coronary calcification into pre-test assessment of the likelihood of coronary artery disease. J Am Coll Cardiol 2020;76:2421–32. https://doi.org/10.1016/j. jacc.2020.09.585 140. Genders TS, Steyerberg EW, Hunink MG, Nieman K, Galema TW, Mollet NR, et al. Prediction model to estimate presence of coronary artery disease: retrospective pooled analysis of existing cohorts. BMJ 2012;344:e3485. https://doi.org/10.1136/ bmj.e3485 141. Zhou J, Zhao J, Li Z, Cong H, Wang C, Zhang H, et al. Coronary calcification improves the estimation for clinical likelihood of obstructive coronary artery disease and avoids unnecessary testing in patients with borderline pretest probability. Eur J Prev Cardiol 2022;29:e105–7. https://doi.org/10.1093/eurjpc/zwab036 142. Winther S, Murphy T, Schmidt SE, Bax JJ, Wijns W, Knuuti J, et al. Performance of the American Heart Association/American College of Cardiology guidelinerecommended pretest probability model for the diagnosis of obstructive coronary artery disease. J Am Heart Assoc 2022:e027260. https://doi.org/10.1161/JAHA.122. 027260 143. Winther S, Schmidt SE, Foldyna B, Mayrhofer T, Rasmussen LD, Dahl JN, et al. Coronary calcium scoring improves risk prediction in patients with suspected obstructive coronary artery disease. J Am Coll Cardiol 2022;80:1965–77. https://doi.org/ 10.1016/j.jacc.2022.08.805 144. Rasmussen LD, Schmidt SE, Knuuti J, Newby DE, Singh T, Nieman K, et al. Exercise electrocardiography for pre-test assessment of the likelihood of coronary artery disease. Heart 2023;110:263–70. https://doi.org/10.1136/heartjnl-2023-322970 145. McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, Trinick TR, et al. A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc Imaging 2015;16:441–8. https://doi.org/10.1093/ ehjci/jeu284 146. Lubbers M, Dedic A, Coenen A, Galema T, Akkerhuis J, Bruning T, et al. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial. Eur Heart J 2016;37:1232–43. https://doi.org/10.1093/eurheartj/ ehv700 147. Banerjee A, Newman DR, Van den Bruel A, Heneghan C. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. Int J Clin Pract 2012;66:477–92. https://doi.org/10.1111/j.1742- 1241.2012.02900.x 148. Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kolh P, Rutjes AWS, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 2018;39:3322–30. https://doi.org/10.1093/eurheartj/ehy267 149. Cole JP, Ellestad MH. Significance of chest pain during treadmill exercise: correlation with coronary events. Am J Cardiol 1978;41:227–32. https://doi.org/10.1016/0002- 9149(78)90161-3 150. Lindow T, Ekström M, Brudin L, Carlén A, Elmberg V, Hedman K. Typical angina during exercise stress testing improves the prediction of future acute coronary syndrome. Clin Physiol Funct Imaging 2021;41:281–91. https://doi.org/10.1111/cpf.12695 151. Agha AM, Pacor J, Grandhi GR, Mszar R, Khan SU, Parikh R, et al. The prognostic value of CAC zero among individuals presenting with chest pain. JACC Cardiovasc Imaging 2022;15:1745–57. https://doi.org/10.1016/j.jcmg.2022.03.031 152. Mortensen MB, Gaur S, Frimmer A, Bøtker HE, Sørensen HT, Kragholm KH, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol 2022;7:36–44. https://doi. org/10.1001/jamacardio.2021.4406 153. Lubbers M, Coenen A, Kofflard M, Bruning T, Kietselaer B, Galema T, et al. Comprehensive cardiac CT with myocardial perfusion imaging versus functional testing in suspected coronary artery disease: the multicenter, randomized CRESCENT-II trial. JACC Cardiovasc Imaging 2018;11:1625–36. https://doi.org/10.1016/j.jcmg.2017. 10.010 154. Zhou J, Li C, Cong H, Duan L, Wang H, Wang C, et al. Comparison of different investigation strategies to defer cardiac testing in patients with stable chest pain. JACC Cardiovasc Imaging 2022;15:91–104. https://doi.org/10.1016/j.jcmg.2021.08.022 155. Heald CL, Fowkes FG, Murray GD, Price JF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis 2006;189:61–9. https://doi.org/10.1016/j.atherosclerosis.2006.03.011 156. Molnár S, Kerényi L, Ritter MA, Magyar MT, Ida Y, Szöllősi Z, et al. Correlations between the atherosclerotic changes of femoral, carotid and coronary arteries: a post mortem study. J Neurol Sci 2009;287:241–5. https://doi.org/10.1016/j.jns.2009.06.001 157. Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibañez B, López-Melgar B, Laclaustra M, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation 2015;131:2104–13. https://doi.org/10. 1161/CIRCULATIONAHA.114.014310 158. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056 Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026